Consoli A - Search Results

1

Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals.

Bomba M, Ciavardelli D, Silvestri E, Canzoniero LM, Lattanzio R, Chiappini P, Piantelli M, Di Ilio C, Consoli A, Sensi SL. Bomba M, et al. Among authors: consoli a. Cell Death Dis. 2013 May 2;4(5):e612. doi: 10.1038/cddis.2013.139. Cell Death Dis. 2013. PMID: 23640454 Free PMC article.

2

[Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].

Consoli A, Di Biagio R. Consoli A, et al. G Ital Cardiol (Rome). 2011 Dec;12(12 Suppl 2):5-9. doi: 10.1714/985.10684. G Ital Cardiol (Rome). 2011. PMID: 22158421 Review. Italian.

3

[Towards evidence-based medicine: large-scale intervention trials with glucagon-like peptide-1 receptor agonists].

Consoli A, Di Biagio R. Consoli A, et al. G Ital Cardiol (Rome). 2012 Dec;13(12 Suppl 1):17S-22S. doi: 10.1714/1203.13333. G Ital Cardiol (Rome). 2012. PMID: 23258125 Italian.

4

Circulating dickkopf-1 in diabetes mellitus: association with platelet activation and effects of improved metabolic control and low-dose aspirin.

Lattanzio S, Santilli F, Liani R, Vazzana N, Ueland T, Di Fulvio P, Formoso G, Consoli A, Aukrust P, Davì G. Lattanzio S, et al. Among authors: consoli a. J Am Heart Assoc. 2014 Jul 18;3(4):e001000. doi: 10.1161/JAHA.114.001000. J Am Heart Assoc. 2014. PMID: 25037197 Free PMC article.

5

Potential side effects to GLP-1 agonists: understanding their safety and tolerability.

Consoli A, Formoso G. Consoli A, et al. Expert Opin Drug Saf. 2015 Feb;14(2):207-18. doi: 10.1517/14740338.2015.987122. Epub 2014 Dec 12. Expert Opin Drug Saf. 2015. PMID: 25496749 Review.

6

[Type 2 diabetes treatment and cardiovascular risk: what can we learn from trials?].

Consoli A, Febo F. Consoli A, et al. G Ital Cardiol (Rome). 2016 Dec;17(12 Suppl 2):20S-27. doi: 10.1714/2616.26912. G Ital Cardiol (Rome). 2016. PMID: 28151518 Italian.

7

A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment.

Consoli A, Formoso G, Baldassarre MPA, Febo F. Consoli A, et al. Expert Opin Drug Saf. 2018 Mar;17(3):293-302. doi: 10.1080/14740338.2018.1428305. Epub 2018 Jan 19. Expert Opin Drug Saf. 2018. PMID: 29334278 Review.

8

Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?

Gentilella R, Pechtner V, Corcos A, Consoli A. Gentilella R, et al. Among authors: consoli a. Diabetes Metab Res Rev. 2019 Jan;35(1):e3070. doi: 10.1002/dmrr.3070. Epub 2018 Oct 4. Diabetes Metab Res Rev. 2019. PMID: 30156747 Review.

9

Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study.

Vadini F, Simeone PG, Boccatonda A, Guagnano MT, Liani R, Tripaldi R, Di Castelnuovo A, Cipollone F, Consoli A, Santilli F. Vadini F, et al. Among authors: consoli a. Int J Obes (Lond). 2020 Jun;44(6):1254-1263. doi: 10.1038/s41366-020-0535-5. Epub 2020 Jan 21. Int J Obes (Lond). 2020. PMID: 31965072 Clinical Trial.

10

Exenatide Once Weekly: Effectiveness, Tolerability, and Discontinuation Predictors in a Real-world Setting.

Di Dalmazi G, Coluzzi S, Baldassarre MPA, Sorbo SE, Dell'Aquila S, Febo F, Ginestra F, Graziano G, Rossi MC, Consoli A, Formoso G. Di Dalmazi G, et al. Among authors: consoli a. Clin Ther. 2020 Sep;42(9):1738-1749.e1. doi: 10.1016/j.clinthera.2020.07.002. Epub 2020 Aug 1. Clin Ther. 2020. PMID: 32753164

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

602 results

Search Page

Filters